Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined
criteria for diagnosis, initiation of therapy, and response, which was established by …

PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study
showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM) …

PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant
lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent …

Herein, we present the final report of a single-center, prospective phase II study evaluating
ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom …

The 2022 European Society of Cardiology (ESC) guidelines [1] are a comprehensive
document, prepared jointly by experts in cardiology and oncology. In the case of oncology …

The phase III ASPEN study demonstrated the comparable efficacy and improved safety of
zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here …

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase
(BTK) inhibitors has led to dramatic improvements in the management of B-cell …